BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29496561)

  • 1. Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes.
    DeFilipp Z; Troschel FM; Qualls DA; Li S; Kuklinski MW; Kempner ME; Hochberg E; Chen YB; El-Jawahri A; Fintelmann FJ
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1741-1747. PubMed ID: 29496561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
    Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
    Armenian SH; Iukuridze A; Teh JB; Mascarenhas K; Herrera A; McCune JS; Zain JM; Mostoufi-Moab S; McCormack S; Slavin TP; Scott JM; Jones LW; Sun CL; Forman SJ; Wong FL; Nakamura R
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):962-972. PubMed ID: 32212263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcopenia and low muscle radiodensity associate with impaired FEV
    Mishra A; Bigam KD; Extermann M; Faramand R; Thomas K; Pidala JA; Baracos VE
    J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1570-1579. PubMed ID: 32729255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Economic Burden Associated with Transplantation-Related Complications.
    Perales MA; Bonafede M; Cai Q; Garfin PM; McMorrow D; Josephson NC; Richhariya A
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1788-1794. PubMed ID: 28688917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution and impact of sarcopenia in severe aplastic anaemia survivors following allogeneic haematopoietic cell transplantation.
    Chen D; Yuan Z; Guo Y; Liu W; Cheng Z; Ye L; Mo W; Wei X
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1094-1107. PubMed ID: 38526005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
    Pemmaraju N; Tanaka MF; Ravandi F; Lin H; Baladandayuthapani V; Rondon G; Giralt SA; Chen J; Pierce S; Cortes J; Kantarjian H; Champlin RE; De Lima M; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):485-92. PubMed ID: 23769669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low subcutaneous adipose tissue and myosteatosis are prognostic factors after allogeneic hematopoietic stem cell transplantation.
    Barajas Ordonez F; Zeller Y; Wolleschak D; Hinnerichs M; Rodríguez-Feria P; Mougiakakos D; Aghayev A; Kardas H; Mikusko M; Borggrefe J; Surov A
    Clin Nutr ESPEN; 2024 Jun; 61():274-280. PubMed ID: 38777443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation.
    Zając-Spychała O; Wachowiak J; Pieczonka A; Siewiera K; Frączkiewicz J; Kałwak K; Gorczyńska E; Chybicka A; Czyżewski K; Jachna-Sawicka K; Wysocki M; Klepacka J; Goździk J; Zaucha-Prażmo A; Kowalczyk JR; Styczyński J
    Transpl Infect Dis; 2016 Oct; 18(5):690-698. PubMed ID: 27479544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.
    Armenian SH; Xiao M; Berano Teh J; Lee B; Chang HA; Mascarenhas K; Lee S; Iukuridze A; Xie JJ; Scott JM; Jones LW; Lennie Wong F; Forman SJ; Nakamura R
    J Natl Cancer Inst; 2019 Aug; 111(8):837-844. PubMed ID: 30951603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.
    Ebeling PR; Thomas DM; Erbas B; Hopper JL; Szer J; Grigg AP
    J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
    Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
    Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
    Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.
    Dhakal B; Giri S; Levin A; Rein L; Fenske TS; Chhabra S; Shah NN; Szabo A; D'Souza A; Pasquini M; Hari P; Hamadani M
    JAMA Netw Open; 2019 Jul; 2(7):e196476. PubMed ID: 31276175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of second allogeneic hematopoietic cell transplantation.
    Khera N; Storer B; Sandmaier BM; Chapko MK; Lee SJ
    Transplantation; 2013 Jul; 96(1):108-15. PubMed ID: 23694949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
    Moustafa MA; Ramdial JL; Tsalatsanis A; Khimani F; Dholaria B; Bojanini L; Brooks T; Zain J; Bennani NN; Braunstein Z; Brammer JE; Beitinjaneh A; Jagadeesh D; Weng WK; Kumar A; Kharfan-Dabaja MA; Ahmed S; Murthy HS
    Transplant Cell Ther; 2024 May; 30(5):516.e1-516.e10. PubMed ID: 38431075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation.
    Yao S; Smiley SL; West K; Lamonica D; Battiwalla M; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1130-7. PubMed ID: 20188201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.